MedTrace Logo

A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B

NCT06041022 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-09-18

No results posted yet for this study

Summary

Establishment and validation of the non-invasive model to predict antiviral therapy in the gray zone of chronic hepatitis B

Conditions

  • Hepatitis B, Chronic

Interventions

OTHER

Exposure factors

Including demographical data, laboratory features and liver histological indicators.

Sponsors & Collaborators

  • Linyi People's Hospital

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Yu-Chen Fan, MD,PhD · Qilu Hospital of Shandong University

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2023-11-01
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041022 on ClinicalTrials.gov